- Home
- SBR vs NRIX Comparison
SBR vs NRIX Comparison
Compare SBR & NRIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SBR
- NRIX
- Stock Information
- Founded
- SBR 1982
- NRIX 2009
- Country
- SBR United States
- NRIX United States
- Employees
- SBR N/A
- NRIX N/A
- Industry
- SBR Oil & Gas Production
- NRIX Biotechnology: Pharmaceutical Preparations
- Sector
- SBR Energy
- NRIX Health Care
- Exchange
- SBR Nasdaq
- NRIX Nasdaq
- Market Cap
- SBR 941.4M
- NRIX 1.1B
- IPO Year
- SBR N/A
- NRIX 2020
- Fundamental
- Price
- SBR $67.28
- NRIX $11.56
- Analyst Decision
- SBR
- NRIX Strong Buy
- Analyst Count
- SBR 0
- NRIX 17
- Target Price
- SBR N/A
- NRIX $30.71
- AVG Volume (30 Days)
- SBR 38.7K
- NRIX 1.3M
- Earning Date
- SBR 01-01-0001
- NRIX 04-08-2025
- Dividend Yield
- SBR 7.96%
- NRIX N/A
- EPS Growth
- SBR N/A
- NRIX N/A
- EPS
- SBR 5.46
- NRIX N/A
- Revenue
- SBR $83,171,096.00
- NRIX $56,417,000.00
- Revenue This Year
- SBR N/A
- NRIX $12.84
- Revenue Next Year
- SBR N/A
- NRIX N/A
- P/E Ratio
- SBR $12.26
- NRIX N/A
- Revenue Growth
- SBR N/A
- NRIX N/A
- 52 Week Low
- SBR $58.25
- NRIX $8.18
- 52 Week High
- SBR $70.20
- NRIX $29.56
- Technical
- Relative Strength Index (RSI)
- SBR 57.22
- NRIX 51.19
- Support Level
- SBR $64.83
- NRIX $9.23
- Resistance Level
- SBR $67.23
- NRIX $12.38
- Average True Range (ATR)
- SBR 2.14
- NRIX 0.95
- MACD
- SBR 0.42
- NRIX 0.42
- Stochastic Oscillator
- SBR 98.81
- NRIX 80.48
About SBR Sabine Royalty Trust
Sabine Royalty Trust is an express trust which is formed to receive Sabine Corporation's royalty and mineral interests, including landowner's royalties, overriding royalty interests, minerals production payments and any other similar, non-participatory interests, in certain Royalty Properties. The trusts producing and proved undeveloped oil and gas royalty properties are located in Florida, Louisiana, Mississippi, New Mexico, Oklahoma, and Texas.
About NRIX Nurix Therapeutics Inc. Common stock
Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies.